| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Richard Aldrich last filed a Form 4 in December 2018, as Director at KALV. The filings on record cover 2 companies. From March 2015 to December 2018, the filings on record show 13 open-market purchases and 0 sales. Richard Aldrich's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 934,484 shares of KALV. Net of sales, the KALV filings show accumulation of 565,065 shares.
Shares as reported in the last Form 4 for each company; the most recent is from December 2018. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 16, 2016 | TPST Tempest Therapeutics, Inc. | Director | Buy | 59,029 | $7.90 | $466,104.20 | +36.3% | |
| Mar 14, 2016 | TPST Tempest Therapeutics, Inc. | Director | Buy | 162,732 | $7.60 | $1,237,092.00 | New | |
| Apr 8, 2015 | TPST Tempest Therapeutics, Inc. | Director | Buy | 2,500 | $29.97 | $74,925.00 | +12.6% |